A team of biologists from San Diego State University has developed a platform for identifying drugs that could prove to be effective against a variety of viral diseases.
The team used dengue virus as an example and they identified a novel drug which may someday be used to combat the disease.
Over the past several years, the researchers led by biologist Roland Wolkowicz have been developing cell-based platforms that can be used to monitor the biomolecular activity of viruses inside their host cells.
Based on a platform previously created for HIV, Wolkowicz and his team built a new platform for dengue virus.
The Wolkowicz team's platform screens host cells to detect whether or not a particular protein function of dengue, known as pre-membrane protein (prM) cleavage, has occurred.
The prM cleavage process is important for new viral particles to be able to infect a host cell.
Preventing the cleavage from happening could effectively stop the virus in its tracks.
"Cleavage is absolutely critical to the virus's life cycle. While the role of prM cleavage is not completely understood, new particles won't mature without it. By blocking prM cleavage, you clearly diminish the virus's ability to infect other cells," explained Wolkowicz.
His lab's technique embedded two biomolecular tags - a "red" tag and a "green" tag, so-called because of the fluorescent antibodies that detect them - inside an infected cell.
The tags are designed in such a way that if cleavage occurs, one of them falls off.
Using this technique, the team tested 1,280 drug compounds to see whether any of them could block prM cleavage to yield a green tag, preventing a critical step in the dengue viral life cycle.
According to Wolkowicz, the results demonstrate just how robust and powerful their platform is for identifying drug candidates for fighting viruses.
Dengue infects between 50 and 100 million people each year and has no known vaccine or treatment.
Some 22,000 people die each year from the disease, says a World Health Organisation (WHO) report.
The studies were published in the Journal of Biomolecular Screening and the Journal of Visualized Experiments.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
